Vext Science (VEXT) AI Stock Analysis

• Market Cap: C$69.32M
• Dividend Yield: N/A
• Average Volume (3M): 49.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: 36.50%
• EPS Growth: -306.47%
• Country: CA
• Employees: 173
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 180,306,050
• 10 Day Avg. Volume: 82,502
• 30 Day Avg. Volume: 49,040
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: C$0.50 ▲(78.57% Upside)

Vext Science's overall stock score reflects a blend of strong technical indicators and positive earnings call insights, particularly in Ohio, which are offset by concerns over profitability and valuation. The company's ability to capitalize on growth opportunities while addressing profitability challenges will be crucial for future performance.

Vext Science Business Overview & Revenue Model

Company Description

Vext Science (VEXT) is a cannabis-focused company engaged in the production and distribution of a diverse range of cannabis products. Operating primarily in the United States, Vext specializes in the manufacturing of high-quality cannabis flower, oils, and infused products, catering to both medical and recreational markets. The company is committed to leveraging innovative cultivation techniques and advanced extraction methods to ensure product consistency and efficacy, while also emphasizing quality and compliance with regulatory standards in the cannabis industry.

How the Company Makes Money

Vext Science generates revenue through multiple streams, primarily from the sale of its cannabis products, including dried flower, oils, and edibles. The company has established a strong presence in key markets, allowing it to capitalize on the increasing demand for cannabis products. Additionally, VEXT engages in wholesale distribution, supplying its products to dispensaries, which contributes significantly to its revenue. The company may also benefit from strategic partnerships with other cannabis operators and retailers, enhancing its market reach and operational efficiency. Furthermore, Vext Science's commitment to quality and compliance helps to build brand loyalty and repeat business, which are essential for sustaining its revenue growth.

Vext Science Financial Statement Overview

Summary

Vext Science shows revenue growth but faces profitability challenges with negative net profit and EBIT margins. The balance sheet is moderately leveraged, and while cash flow has improved, historical volatility poses sustainability risks.

Income Statement

Vext Science shows fluctuating financial performance with recent revenue growth of 8.8% in the TTM period. The gross profit margin decreased from the previous year, and the company is currently experiencing negative net profit and EBIT margins, indicating profitability challenges. Despite some revenue growth, the declining profitability metrics present significant concerns.

Balance Sheet

The balance sheet reveals moderate financial leverage with a debt-to-equity ratio of 0.52 in the TTM period, indicating manageable debt levels. However, the equity ratio has declined over time, reflecting increased liabilities. Return on equity is negative due to net losses, highlighting challenges in generating returns for shareholders.

Cash Flow

Vext Science has shown improvement in operating cash flow, with a positive free cash flow in the TTM period. The operating cash flow to net income ratio indicates strong cash generation relative to reported losses, suggesting efficient cash management. However, the historical volatility in free cash flow growth poses a risk to sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.15M	36.00M	34.81M	35.41M	37.24M	25.19M
Gross Profit	13.25M	8.98M	12.04M	23.10M	18.69M	11.20M
EBITDA	6.27M	-2.02M	16.77M	15.03M	12.80M	5.52M
Net Income	-16.52M	-22.44M	4.40M	10.92M	4.99M	2.13M
Balance Sheet
Total Assets	132.88M	136.97M	149.56M	120.52M	83.70M	55.45M
Cash, Cash Equivalents and Short-Term Investments	4.55M	4.62M	8.72M	5.93M	6.47M	1.75M
Total Debt	35.62M	39.52M	38.60M	38.15M	14.10M	11.49M
Total Liabilities	61.84M	61.23M	54.58M	48.60M	24.31M	19.14M
Stockholders Equity	71.04M	75.74M	94.98M	71.92M	59.39M	36.31M
Cash Flow
Free Cash Flow	8.65M	1.82M	1.69M	-2.94M	-7.10M	-964.90K
Operating Cash Flow	11.03M	3.29M	4.42M	5.92M	11.68M	3.10M
Investing Cash Flow	-4.99M	-5.44M	-4.82M	-30.31M	-27.10M	-12.90M
Financing Cash Flow	-4.88M	-1.95M	3.19M	23.86M	20.14M	4.26M

Vext Science Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Neutral. The current price of 0.28 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.31, and above the 200-day MA of 0.20, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.91 is Neutral, neither overbought nor oversold. The STOCH value of 40.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:VEXT.

Vext Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	―	$74.97M	5.00	22.76%	―	-0.53%	―
VEXT	―	C$69.32M	―	-20.91%	―	36.50%	-306.47%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ROMJ	―	$36.95M	203.70	0.61%	―	34.19%	―
CXXI	―	C$62.42M	―	-10.63%	―	21.71%	18.75%
LABS	―	$31.56M	-3.59	-19.58%	―	17.74%	37.61%
GWAY	―	C$23.14M	―	-15.75%	―	26.75%	61.79%

Vext Science Corporate Events

Vext Science Expands Ohio Footprint with Portsmouth Dispensary Acquisition

Vext Science, Inc. has secured state approval for the ownership transfer of the Herbal Wellness Center dispensary in Portsmouth, Ohio, marking its fifth fully consolidated dispensary in the state. This move is part of Vext’s strategic expansion in Ohio, aiming to reach the state’s eight-store cap by late 2025 or early 2026. The Portsmouth location, which includes a drive-thru, enhances Vext’s retail footprint and supports its vertically integrated platform, contributing to margin expansion and cash flow generation. With ongoing construction and permitting for three additional locations, Vext is poised to operate the state maximum of eight dispensaries, reinforcing its position in the growing Ohio cannabis market.

The most recent analyst rating on (TSE:VEXT) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science Earnings Call: Ohio Growth Shines

The recent earnings call for Vext Science highlighted a mixed sentiment, with strong performance in Ohio driving significant revenue growth and improved EBITDA margins. However, challenges in the Arizona market and a decline in wholesale sales were noted as hurdles. Overall, the positive growth in Ohio and operational improvements slightly outweighed the issues faced in Arizona.

Vext Science Reports Record Q2 2025 Revenue

Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, specializing in cultivation, manufacturing, and retail of cannabis products, including the Vapen™ brand.

Vext Science Reports Record Q2 2025 Financial Performance

Vext Science, Inc. reported record financial performance in Q2 2025, with revenue growing 59% year-over-year to $13.4 million, driven by strong momentum in Ohio and disciplined operations in Arizona. The company’s adjusted EBITDA more than tripled to $4.1 million, and operating cash flow reached $4.2 million, achieving a 31% cash flow margin, one of the highest in the industry. Vext is strengthening its retail footprint in Ohio, with plans to reach the state dispensary license cap by early 2026, positioning itself for sustained growth in the expanding adult-use market.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.

Vext Science to Release Q2 2025 Financial Results on August 20

Vext Science, Inc. announced it will release its financial results for the second quarter of 2025 on August 20, 2025. The company will host a conference call and webcast to discuss these results, which could provide insights into its operational performance and strategic positioning in the cannabis industry. This announcement is significant for stakeholders as it may impact perceptions of Vext’s financial health and future growth prospects in its core markets.

The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.